Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells

Parsons, P. G., Hansen, C., Fairlie, D. P., West, M. L., Danoy, P. A. C., Sturm, R. A., Dunn, I. S., Pedley, J. and Ablett, E. M. (1997) Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochemical Pharmacology, 53 11: 1719-1724. doi:10.1016/S0006-2952(97)00016-6


Author Parsons, P. G.
Hansen, C.
Fairlie, D. P.
West, M. L.
Danoy, P. A. C.
Sturm, R. A.
Dunn, I. S.
Pedley, J.
Ablett, E. M.
Title Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells
Journal name Biochemical Pharmacology   Check publisher's open access policy
ISSN 0006-2952
1873-2968
Publication date 1997-06
Sub-type Article (original research)
DOI 10.1016/S0006-2952(97)00016-6
Volume 53
Issue 11
Start page 1719
End page 1724
Total pages 6
Place of publication Philadelphia, PA, United States
Publisher Elsevier
Language eng
Formatted abstract
Azelaic bishydroxamic acid (ABHA), a potent differentiating agent for lymphoid cells, was selectively toxic for 5 human tumor cell lines and transformed human melanocytes and keratinocytes (dose for 37% survival, D 37, 30-100 μg/mL) compared with normal cells (melanocytes, fibroblasts; D 37 > 300 μg/mL). Dendritic morphology was the only indicator found for increased differentiation, markers for the pigmentation pathway being unchanged or inhibited by ABHA. In contrast to hexamethylene bisacetamide and azelaic acid. ABHA significantly increased the HIV LTR, SV40 and c-fos promoter activities during a 24 hr treatment. Metallothionein promoter activity was enhanced by 5 hr treatment with ABHA in a sensitive melanoma cell line (MM96L) but was inhibited in a more resistant line (HeLa); c-fos promoter activity was inhibited in HeLa during this time. Transcription from a p53 binding response element was inhibited in MM96L by a 24 hr ABHA treatment but enhanced in HeLa. ABHA may represent a structural prototype for designing more potent and selective anti-melanoma agents.
Keyword Azelaic bishydroxamic acid
Differentiation
Human melanoma
Selective toxicity
Transcription
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Institute for Molecular Bioscience - Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 35 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 38 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 08 Jul 2011, 10:19:09 EST by System User on behalf of Institute for Molecular Bioscience